Literature DB >> 2894968

Somatostatin and octreotide: literature review and description of therapeutic activity in pancreatic neoplasia.

S M Longnecker1.   

Abstract

The somatostatins represent endogenous substances that serve a diversity of functions in the body. These activities are just beginning to be understood and could have major implications in the treatment of human disease. Their chief pharmacologic activities lie in the modification or modulation of protein hormone synthesis of the gastrointestinal system; a great many other systems may be involved as well. Since the discovery of the therapeutic potentials of naturally isolated somatostatins, attempts have been made to design newer analogs more conducive to practical use. Such an example is long-acting somatostatin analog octreotide. Literature has recently begun to appear describing the therapeutic activities of this and other similar compounds and the first steps to understanding their clinical pharmacology are being taken. Surprising activity has been found in the palliative treatment of a wide variety of formerly resistant gastrointestinal syndromes and endocrine tumors. These activities may have considerable future impact on the treatment of disease involving hormonal imbalance or inappropriate secretion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2894968     DOI: 10.1177/106002808802200201

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  10 in total

1.  Stability of somatostatin in total parenteral nutrition.

Authors:  J B Montoro; R Galard; R Catalan; J Martinez; P Salvador; P Sabin
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

Review 2.  Somatostatin and analogues in the treatment of cancer. A review.

Authors:  B M Evers; D Parekh; C M Townsend; J C Thompson
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

3.  Effect of octreotide on dynamic excretion of bile in Chinese acromegalic patients assessed by [99mTc]EHIDA hepatobiliary scan.

Authors:  X F Zhu; A G Harris; M F Yang; Y F Shi; Q Zhou; J Y Xu; J X Zhang
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

4.  Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.

Authors:  Thomas Günther; Michael Culler; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2016-03-11

5.  The adverse effects of octreotide on the healing of colonic anastomoses in rats.

Authors:  A G Türkçapar; S Demirer; N Sengül; S Ersöz; E Kuterdem; N Renda; I Kuzu
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

Review 6.  Somatostatin and somatostatin receptors in the diagnosis and treatment of gliomas.

Authors:  K Lamszus; W Meyerhof; M Westphal
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

7.  Effects of octreotide on circulating islet B cell products in endogenous hyperinsulinism.

Authors:  A J Krentz; J Pace; W Somerville; P M Clark; M Nattrass
Journal:  Postgrad Med J       Date:  1993-09       Impact factor: 2.401

Review 8.  Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours.

Authors:  P Chanson; J Timsit; A G Harris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

Review 9.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

10.  Inhibitory effect of a somatostatin analogue (SMS 201-995) on the growth of androgen-dependent mouse mammary tumor (Shionogi carcinoma 115).

Authors:  S Noguchi; Y Nishizawa; K Motomura; H Inaji; S Imaoka; H Koyama; K Matsumoto
Journal:  Jpn J Cancer Res       Date:  1993-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.